Shots:
- Bio‑Thera reported the dosing of the first patient in a P‑III study assessing the efficacy of BAT8006 vs. the investigator’s choice of single-agent CT in individuals with Pt resistant high‑grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Early clinical Data (N=133; irrespective of FRα expression or treatment history) presented at ASCO’25, from the dose‑escalation and expansion study of BAT8006 demonstrated a mPFS of 7.63mos., ORR of 40.7%, and DCR of 80.5%, with no instances of interstitial lung disease or ocular toxicity
- BAT8006 is an antibody drug conjugate that targets folate receptor α (FRα) and is currently being evaluated for the treatment of Pt resistant ovarian cancer
Ref: PRNewswire | Image: | Press Release
Related News:- Nitinotes Reports the US FDA’s IDE Approval of EndoZip System for Endoscopic Sleeve Gastroplasty
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
